ImmunoGen, Inc.

IMGN
Real-time BATS EXCHANGE - 04/03 03:23:20 pm
3.405USD
-1.73%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Sales 82,3 61,3
EBITDA -88,1 -70,3
Operating profit (EBIT) -92,2 -105
Pre-Tax Profit (EBT) -104 -117
Net income -104 -106
P/E ratio -7,29x -5,45x
EPS ( $ ) -0,70 -0,64
Dividend per Share (  ) - -
Yield - -
Reference price ( $ ) 5,105 3,470
Announcement Date 02/14/2020
11:30am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Debt - -
Finance 174 82,5
Operating income (EBITDA) -88,1 -70,3
Leverage
(Debt/EBITDA)
- -
Capital Expenditure 2,85 5,73
Free Cash Flow (FCF) -91,2 -99,5
Book Value Per Share (BVPS) ( $ ) -0,51 -0,60
Cash Flow per Share (  ) - -
Announcement Date 02/14/2020
11:30am
-
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 605 M $ -
Entreprise Value (EV) 522 M $ 506 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) -5,45x -4,80x
Capitalization / Revenue 9,87x 14,0x
EV / Revenue 8,52x 12,1x
EV / EBITDA -7,43x -6,09x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -5,83x -9,98x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) -171% -305%
Operating Leverage (Delta EBIT / Delta Sales) -0,53x -0,86x
Net Margin (Net Profit / Revenue) -173% -314%
ROA (Net Profit / Asset) -41,0% -54,9%
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   9,35% 13,3%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 4,21x 5,72x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
BNA & Dividende